Dr. Daniel Teper, Immune's CEO commented: "We appreciate the continuous commitment of our investors to support this financing of Immune, which will be dedicated to the advancement of bertilimumab clinical development. We are also implementing a strategy to unlock the value of other assets through the establishment of new, privately-funded companies which will be partially owned by Immune."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.